Pacira ( (PCRX) ) has released its Q1 earnings. Here is a breakdown of the information Pacira presented to its investors.
Don’t Miss TipRanks’ Half Year Sale
- Take advantage of TipRanks Premium for 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
- Make smarter investment decisions with TipRanks' Smart Investor Picks, delivered to your inbox every week.
Pacira BioSciences, Inc., a leader in non-opioid pain therapies, operates within the biopharmaceutical sector, focusing on innovative solutions for pain management.
In its first quarter of 2025, Pacira reported total revenues of $168.9 million, with net product sales driven by its flagship products EXPAREL, ZILRETTA, and iovera°. The company also highlighted strategic advancements, including a favorable patent settlement and a $300 million stock buyback program.
Key financial metrics for the quarter included a net income of $4.8 million and adjusted EBITDA of $44.1 million. The company also reported a significant milestone with the extension of the EXPAREL patent exclusivity to 2039, and the initiation of a Phase 2 study for PCRX-201 targeting osteoarthritis of the knee. Additionally, Pacira completed the acquisition of GQ Bio Therapeutics, enhancing its genetic medicine capabilities.
Looking ahead, Pacira remains focused on its ‘5×30’ strategy, aiming for substantial growth and innovation in the biopharmaceutical landscape. The management’s confidence is reflected in their financial guidance for 2025, projecting total revenues between $725 million and $765 million, with a strong emphasis on expanding market share and advancing their product pipeline.